Radiopharmaceuticals Startup RayzeBio Seeks Public Debut After Raising $400M From Investors
Portfolio Pulse from Vandana Singh
Radiopharmaceuticals startup RayzeBio Inc has filed for an initial public offering (IPO) to raise up to $100 million. The company, which focuses on cancer therapies, plans to list on the Nasdaq under the symbol RYZB. Its lead candidate, RYZ101, is designed to deliver a potent alpha particle radioisotope to tumors. The IPO proceeds will also be used to develop RYZ801 and RYZ811, two radiopharmaceuticals for phase 1 trials in hepatocellular carcinoma. RayzeBio has already secured $418 million in funding from investors including venBio Partners, Venrock Healthcare Capital Partners, Versant Ventures, and Viking Global Investors.
August 25, 2023 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RayzeBio Inc is planning an IPO to raise up to $100 million. The funds will be used to develop its cancer therapies, including its lead candidate RYZ101.
The IPO will provide RayzeBio with additional funds to develop its cancer therapies. This could potentially increase the company's value, making it an attractive investment. However, the success of the IPO and the subsequent development of the therapies are uncertain, hence the score of 1.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100